65,437 trials
Erectile Dysfunction · Cardiovascular Diseases · Male Urogenital Diseases
Primary: Percentage of Participants With Underlying Condition Until Day -1 of the Index PDE5i Prescription — 70.23; 55.73 Percentage of participants — p=<0.001
Injections, Intradermal
Primary: Proportion of Injections Delivered to the Intradermal Layer of the Skin — 1 percentage of injections
Heart Decompensation
Primary: Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality — 321; 345 Participants — p=0.313
Infections, Papillomavirus
Primary: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN1+) and/or Persistent Infection (6 Month+ Definition) Associated With Human…
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Antibody Concentrations Against Pneumococcal Vaccine Serotypes — 2.13; 3.04; 3.24; 1.32 microgram per milliliter
Healthy
Primary: Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz) — 3200; 2940…
Influenza
Primary: Number of Subjects Reporting Fever Grade 2 or Higher — 11; 7 Participants
Myopia
Primary: Comfort on Insertion — 8.7; 8.5 Units on a Scale
Neoplasms · Fatigue
Primary: Change From Baseline in Fatigue Scale-Adolescent (FS-A) Score Categorized According to 1-5 Rating Scale of Resource Use and Resource Helpfulness. — -3; -3; -4; -4 units…
Prostate Cancer
Primary: Time to Disease Progression (TTP) — 6; 11 months
Fever
Primary: Child Temperature (Degrees C)Over 6 Hours — 38.5; 37.2; 36.9 degrees Celcius — p=<0.001
Myopia
Primary: Comfort on Insertion — 8.3; 7.5 Units on a Scale
Atrial Fibrillation
Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Generalized Anxiety Disorder
Primary: Change in Hamilton Anxiety Rating Scale Score — -6.4 units on a scale